Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.

BACKGROUND: Matrix metalloproteinases play a role in regulating cardiac remodeling. We previously reported an association between tissue inhibitor of metalloproteinase 2 (TIMP-2) expression and mitral valve (MV) disease. However, the determinants and prognostic value of mitral TIMP2 after MV surgery...

Full description

Bibliographic Details
Main Authors: Tsung-Hsien Lin, Sheau-Fang Yang, Chaw-Chi Chiu, Ho-Ming Su, Wen-Chol Voon, Chee-Yin Chai, Wen-Ter Lai, Sheng-Hsiung Sheu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3903512?pdf=render
id doaj-33e65834d70a438a9ce36b6ce0636243
record_format Article
spelling doaj-33e65834d70a438a9ce36b6ce06362432020-11-24T21:16:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8628710.1371/journal.pone.0086287Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.Tsung-Hsien LinSheau-Fang YangChaw-Chi ChiuHo-Ming SuWen-Chol VoonChee-Yin ChaiWen-Ter LaiSheng-Hsiung SheuBACKGROUND: Matrix metalloproteinases play a role in regulating cardiac remodeling. We previously reported an association between tissue inhibitor of metalloproteinase 2 (TIMP-2) expression and mitral valve (MV) disease. However, the determinants and prognostic value of mitral TIMP2 after MV surgery are unknown. METHODS: This retrospective study of 164 patients after MV surgery in a tertiary medical center in Taiwan assessed mitral TIMP2 on a semiquantitative scale (0-2) by immunohistochemical staining. The primary endpoints were the composite of cardiovascular death and heart failure admission. RESULTS: Mean age was 50.4±13.7 years. After a mean follow-up period of 101±59 months, primary endpoints had occurred in 25 (15.2%) subjects. Patients with and without primary endpoint events significantly differed in terms of age (56.6±14.4 vs. 49.2±13.4 years, respectively; p = 0.013) and left ventricular end-systolic diameter (LVESD) (39.7±8.2 vs. 35.5±7.5 mm, p = 0.010) at surgery. The TIMP2 had a significant dose-dependent association with development of a primary endpoint (p = 0.002). Kaplan-Meier analysis showed that TIMP2 expression has a significant positive association with primary endpoint-free survival (log-rank test; p = 0.004). Cox regression analysis showed that independent predictors of primary endpoints were TIMP2 (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.12-0.65; p = 0.003), age (HR 1.05; 95% CI 1.02-1.09; p = 0.003) and LVESD (HR 1.05; 95% CI 1.01-1.10; p = 0.020). CONCLUSIONS: The lack of mitral TIMP2 expression is associated with increases in cardiovascular death and heart failure following MV surgery.http://europepmc.org/articles/PMC3903512?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Tsung-Hsien Lin
Sheau-Fang Yang
Chaw-Chi Chiu
Ho-Ming Su
Wen-Chol Voon
Chee-Yin Chai
Wen-Ter Lai
Sheng-Hsiung Sheu
spellingShingle Tsung-Hsien Lin
Sheau-Fang Yang
Chaw-Chi Chiu
Ho-Ming Su
Wen-Chol Voon
Chee-Yin Chai
Wen-Ter Lai
Sheng-Hsiung Sheu
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
PLoS ONE
author_facet Tsung-Hsien Lin
Sheau-Fang Yang
Chaw-Chi Chiu
Ho-Ming Su
Wen-Chol Voon
Chee-Yin Chai
Wen-Ter Lai
Sheng-Hsiung Sheu
author_sort Tsung-Hsien Lin
title Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
title_short Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
title_full Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
title_fullStr Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
title_full_unstemmed Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
title_sort mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description BACKGROUND: Matrix metalloproteinases play a role in regulating cardiac remodeling. We previously reported an association between tissue inhibitor of metalloproteinase 2 (TIMP-2) expression and mitral valve (MV) disease. However, the determinants and prognostic value of mitral TIMP2 after MV surgery are unknown. METHODS: This retrospective study of 164 patients after MV surgery in a tertiary medical center in Taiwan assessed mitral TIMP2 on a semiquantitative scale (0-2) by immunohistochemical staining. The primary endpoints were the composite of cardiovascular death and heart failure admission. RESULTS: Mean age was 50.4±13.7 years. After a mean follow-up period of 101±59 months, primary endpoints had occurred in 25 (15.2%) subjects. Patients with and without primary endpoint events significantly differed in terms of age (56.6±14.4 vs. 49.2±13.4 years, respectively; p = 0.013) and left ventricular end-systolic diameter (LVESD) (39.7±8.2 vs. 35.5±7.5 mm, p = 0.010) at surgery. The TIMP2 had a significant dose-dependent association with development of a primary endpoint (p = 0.002). Kaplan-Meier analysis showed that TIMP2 expression has a significant positive association with primary endpoint-free survival (log-rank test; p = 0.004). Cox regression analysis showed that independent predictors of primary endpoints were TIMP2 (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.12-0.65; p = 0.003), age (HR 1.05; 95% CI 1.02-1.09; p = 0.003) and LVESD (HR 1.05; 95% CI 1.01-1.10; p = 0.020). CONCLUSIONS: The lack of mitral TIMP2 expression is associated with increases in cardiovascular death and heart failure following MV surgery.
url http://europepmc.org/articles/PMC3903512?pdf=render
work_keys_str_mv AT tsunghsienlin mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT sheaufangyang mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT chawchichiu mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT homingsu mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT wencholvoon mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT cheeyinchai mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT wenterlai mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
AT shenghsiungsheu mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome
_version_ 1726015113850257408